Ariad Pharmaceuticals (NASDAQ:ARIA) shareholders have had a rough run over the past year, with the stock falling from highs over $20 per share to about $7 per share today. Its drug Iclusig has been plagued by any number of difficulties, with safety concerns leading the FDA to pull the drug off the market briefly before returning it with a stronger health warning.

But Ariad shareholders finally got some good news today: In a phase 2 trial in patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors with KIT exon 11 mutations, 50% of patients with that mutation displayed some form of clinical benefit from the drug, and the FDA also lifted a partial clinical hold on patient enrollment.

In this video, from Monday's Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson talk about the results and what they mean for Ariad shareholders.

Even if Ariad bounces back to its previous highs, it may have serious trouble keeping up with this top stock.
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.